Bristol Myers' Opdivo Shows Improved Clinical Benefits In Bladder Cancer At Three Years

Bristol-Myers Squibb Co BMY announced three-year follow-up results from the Phase 3 CheckMate -274 Phase 3 trial of Opdivo compared to placebo for muscle-invasive urothelial carcinoma at a high risk of recurrence after radical resection.
Opdivo more than doubled the average length of time patients lived without disease recurrence, demonstrating a median disease-free survival of 22.0 months compared to 10.9 months with a placebo. Patients whose tumor cells expressed PD-L1 ≥1% remained disease-free for more than six times as long as placebo.
Related: Revlimid Generic Competition Hurts Bristol Myers' Q4 Earnings, Issues Annual Outlook Within Expected Range.
Opdivo showed a median NUTRFS, defined as the time patients lived without disease recurrence outside of the bladder, ureters, or renal pelvis, of 25.9 months compared to 13.7 months for placebo.
Median DMFS, defined as the time patients live without cancer spreading from the primary tumor to distant organs or lymph nodes, was 47.1 months with Opdivo vs. 28.7 months with placebo.
Price Action: BMY shares are up 0.21% at $71.00 on the last check Friday.